摘要
目的探究A型肉毒素联合复方倍他米松治疗增生性瘢痕患者的临床效果。方法此次的117例研究对象均于我院收治的增生性瘢痕患者中选取,选例时间为2019年6月至2020年12月,将其分为对照组(58例)和观察组(59例),分组主要依据随机数字表法统一进行。对照组患者予以复方倍他米松注射液,观察组患者在对照组的基础上予以注射用A型肉毒素,两组均治疗2个月,并随访1个月。比较两组治疗后的临床疗效;治疗前后的皮损厚度、痛痒严重程度和临床相关指标改善情况;治疗期间的不良反应发生情况和随访期间的复发情况。结果治疗后,观察组总有效率为94.92%,显著高于对照组的75.86%;与治疗前相比,治疗后两组患者的皮损厚度及VAS评分均降低,且观察组低于对照组;治疗后观察组患者瘢痕体积、痛痒觉、硬度及自我评价评分均高于对照组;随访期间观察组患者的复发率为0.00%,显著低于对照组的8.62%(P<0.05)。结论A型肉毒素联合复方倍他米松治疗增生性瘢痕可有效软化瘢痕,促进瘢痕组织恢复,减轻患者的痛痒感,降低复发风险,安全性高。
Objective To explore the clinical effect of type A botulinum toxin combined with compound betamethasone in the treatment of hypertrophic scar patients.Methods The 117 study subjects were selected from the hypertrophic scar patients admitted to our hospital.The selection time was from June 2019 to December 2020.They were divided into a control group (58 cases) and an observation group (59 cases).(Example),the grouping is mainly carried out in a unified manner based on the random number table method.Patients in the control group received compound betamethasone injection,and patients in the observation group received botulinum toxin type A injection on the basis of the control group.Both groups were treated for 2 months and followed up for 1 month.The clinical efficacy of the two groups after treatment were compared;the thickness of the skin lesions,the severity of pain and itching and the improvement of clinical related indicators before and after treatment;the occurrence of adverse reactions during the treatment and the recurrence during the follow-up period.Results After treatment,the total effective rate of the observation group was 94.92%,which was significantly higher than the 75.86% of the control group.Compared with before treatment,the skin lesion thickness and VAS scores of the two groups of patients were reduced after treatment,and the observation group was lower than the control group After treatment,the scar volume,pain,hardness,and self-evaluation scores of the observation group were higher than those of the control group;the recurrence rate of the observation group during the follow-up period was 0.00%,which was significantly lower than the control group’s 8.62% (P<0.05).Conclusion Botulinum toxin type A combined with compound betamethasone in the treatment of hypertrophic scars can effectively soften the scar,promote the recovery of scar tissue,reduce the pain and itching of patients,reduce the risk of recurrence,and have high safety.
作者
朱凌
郑燕萍
吴超
ZHU Ling;ZHENG Yan-ping;WU Chao(Department of Plastic Surgery,Boai Hospital,Zhongshan City,Guangdong Province,528400,China)
出处
《中国医疗美容》
2022年第1期33-36,共4页
China Medical Cosmetology
关键词
A型肉毒素
复方倍他米松
增生性瘢痕
痛痒感
botulinum toxin type A
compound betamethasone
hypertrophic scar
pain and itching
